Inovio Pharmaceuticals (INO) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Inovio Pharmaceuticals (INO) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 56.6% versus a loss of 67.6%. Over five years, INO leads with a -98.6% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($125.2 million vs $118.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INO | TNXP |
|---|---|---|
| Share price | $1.15 | $7.30 |
| Market cap | $118.91M | $125.20M |
| 1-day change | +5.50% | +0.27% |
| YTD return | -33.91% | -53.27% |
| 1-year return | -56.60% | -67.61% |
| 5-year return | -98.63% | -100.00% |
| EPS (TTM) | $-0.90 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.72 | $22.38 |
| 52-week low | $0.56 | $7.10 |
| Distance from 52-week high | -57.72% | -67.38% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +175.65% | +509.59% |
| Average volume | 3.90M | 542.97K |
| Shares outstanding | 103.40M | 17.15M |
| Employees | 112 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INO has outperformed TNXP by 11.0 percentage points over the past year.
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
INO vs TNXP FAQ
Which is bigger, Inovio Pharmaceuticals or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $125.20M compared with $118.91M for Inovio Pharmaceuticals (INO).
Which stock has performed better over the past year, INO or TNXP?
INO returned -56.60% over the past 12 months, compared with -67.61% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Inovio Pharmaceuticals and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.